Cover Image
市場調查報告書

高尿酸血症:開發中產品分析

Hyperuricemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200961
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
高尿酸血症:開發中產品分析 Hyperuricemia - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 71 Pages
簡介

所謂高尿酸血症,是血液中的尿酸濃度過高的狀態。主要的症狀,是關節炎(關節紅腫痛)和發熱,發冷,倦怠感,(伴隨腎結石)腎臟疾病等。主要的罹病素質,有年齡和家族病史,部分醫藥品等。主要的治療方法是非類固醇系抗發炎劑(NSAID)和皮質類固醇的藥物治療。

本報告提供全球各國的高尿酸血症治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等。

簡介

  • 調查範圍

高尿酸血症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

高尿酸血症:企業開發中的治療藥

高尿酸血症:大學/機關研究中的治療藥

高尿酸血症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高尿酸血症:企業開發中的產品

高尿酸血症:大學/機關研究中的產品

高尿酸血症的治療藥開發企業

  • AstraZeneca Plc
  • CymaBay Therapeutics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Nippon Chemipher
  • Polaris Pharmaceuticals, Inc.
  • 武田藥品工業
  • TEIJIN FIBERS製藥

高尿酸血症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高尿酸血症:最近的開發平台趨勢

高尿酸血症:暫停中的計劃

高尿酸血症:開發中止的產品

高尿酸血症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8510IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 4 and 4 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Hyperuricemia.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperuricemia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperuricemia - Overview
    • Pipeline Products for Hyperuricemia - Comparative Analysis
  • Hyperuricemia - Therapeutics under Development by Companies
  • Hyperuricemia - Therapeutics under Investigation by Universities/Institutes
  • Hyperuricemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hyperuricemia - Products under Development by Companies
  • Hyperuricemia - Products under Investigation by Universities/Institutes
  • Hyperuricemia - Companies Involved in Therapeutics Development
    • Allena Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • CymaBay Therapeutics, Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Nippon Chemiphar Co., Ltd.
    • Nobelpharma Co., Ltd.
    • Polaris Pharmaceuticals, Inc.
    • Teijin Pharma Limited
  • Hyperuricemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (allopurinol + lesinurad) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALLN-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arhalofenate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • febuxostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPH-367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NC-2500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NC-2700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegadricase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pyruvic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-4640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMX-049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verinurad - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperuricemia - Dormant Projects
  • Hyperuricemia - Discontinued Products
  • Hyperuricemia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland
      • May 23, 2016: Teijin Pharma's Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
      • Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
      • Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe
      • Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
      • Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
      • Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
      • Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
      • Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
      • May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
      • Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
      • Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan
      • Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada
      • Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe
      • Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperuricemia, H2 2016
  • Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hyperuricemia - Pipeline by Allena Pharmaceuticals, Inc., H2 2016
  • Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2016
  • Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
  • Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
  • Hyperuricemia - Pipeline by Nobelpharma Co., Ltd., H2 2016
  • Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Hyperuricemia - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hyperuricemia - Dormant Projects, H2 2016
  • Hyperuricemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hyperuricemia, H2 2016
  • Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top